Hillsdale Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

Hillsdale Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-310	Closed	-$7.32K	–	699
2023 Q4	$7.32K	Sell	310 -30	-9%	-$534	﹤0.01%	466
2023 Q3	$5.07K	Buy	+340	New	+$4.51K	﹤0.01%	510
2021 Q1	–	Sell	-123,300	Closed	-$708K	–	703
2020 Q4	$708K	Sell	123,300 -40,000	-24%	-$303K	0.07%	263
2020 Q3	$1.18M	Sell	163,300 -53,000	-25%	-$283K	0.12%	169
2020 Q2	$755K	Buy	+216,300	New	+$624K	0.07%	240
2018 Q2	–	Sell	-8,000	Closed	-$104K	–	563
2018 Q1	$104K	Buy	+8,000	New	+$99.4K	0.01%	281

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hillsdale Investment Management's CBAY Position: Q1 2024 in Review

Hillsdale Investment Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 310 shares — an estimated $7.32K sold.

Hillsdale Investment Management first reported a position in CBAY in Q1 2018 and held it in 6 quarters. The position peaked at $1.18M in Q3 2020. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Hillsdale Investment Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Hillsdale Investment Management sold 310 Cymabay Therapeutics shares in Q1 2024, an estimated $7.32K.
Hillsdale Investment Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 6 quarters.
Hillsdale Investment Management's Cymabay Therapeutics position peaked at $1.18M in Q3 2020.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Hillsdale Investment Management's 13F filing for Q1 2024, filed 10 May 2024.